

***STAPHYLOCOCCUS AUREUS***  
**BACTERIAL RESISTANCE TO**  
**SILVER NANOPARTICLE:**  
**THE EMERGENCE AND**  
**THE MECHANISMS OF RESISTANCE**

by

Elizabeth Valentin

A thesis submitted in fulfilment of the requirements for the award of  
Doctor of Philosophy

The itthree Institute  
Faculty of Science  
University of Technology Sydney  
July 2020



# Certificate of Original Authorship

I, Elizabeth Valentin, declare that this thesis, is submitted in fulfilment of the requirements for the award of Doctor of Philosophy in the itthree Institute, Faculty of Science at the University of Technology Sydney.

This thesis is wholly my own work unless otherwise reference or acknowledged. In addition, I certify that all information sources and literature used are indicated in the thesis.

This document has not been submitted for qualifications at any other academic institution.

This research is supported by the Australian Government Research Training Program, Australian Research Council Discovery Project (DP 180100474), the UTS International Research and the UTS President's Scholarships.

Production Note:

Signature removed prior to publication.

**Elizabeth Valentin**

July 2020



*To Roy*



# Acknowledgment

*“I praise You because I am fearfully and wonderfully made; Your works are wonderful, I know that full well” – Psalm 139: 14*

It is an incredible feeling to finally write this acknowledgment section as it indicates that my PhD journey is closing to an end after 3.5 years. Looking back, it has been a very tough and challenging journey, and at the same time, very rewarding, particularly because I changed path from biochemical engineering to microbiology. This PhD work and completion would only be a sole imagination without the support and help from the people that I would like to give my gratitude to.

First, I would like to thank my primary supervisor, Dr. Cindy Gunawan. Thank you for taking me on board and for your trust in me to do this PhD project in the first place. Thank you for being a role model in an academic field, something I did not expect to have when I enrolled as a PhD student. I would say that you are probably one of the most accessible supervisors I have ever have so far and the one that is always up for discussion. Also, I would never forget your excitement in science, regardless of explainable or unexplainable the results were. This gave me a boost to stay excited and curious as well. Lastly, thank you for reading and improving the quality of my writing.

Huge thanks and appreciation for my co-supervisor, Dr. Amy Bottomley, who taught me fundamental molecular microbiology techniques in the laboratory. This gave me hands-on experiences that I truly appreciate. Thank you for putting a big effort for honest feedbacks on mostly everything, but particularly for this thesis. Your invaluable feedback has helped me to improve my work. I would like to also thank my other co-supervisor, Prof. Liz Harry. Thank you for asking questions that quite unthinkable sometimes and letting me ponder the bigger picture of my work.

Ultimately, I would like to thank all my supervisors for their tremendous support and understanding especially when my husband and I were expecting our little one towards the end of my PhD.

I would like to thank my thesis reviewer, Prof. Kwang-Leong Choy from University of College London (UCL), United Kingdom and Prof. Cordelia Selomulya from University of New South Wales (UNSW), Australia for their honest and constructive comments. Thank you for giving this thesis different perspective and help elevate the significance of the work.

I am very grateful for Assoc. Prof. Scott Rice, Dr. Gayatri Shankar Chilambi, Dr. Xinyi Zhu, Dr. Xianghui Liu, and Dr. Cai Zhao. Thank you for the discussion, feedback, and help particularly during the genomic and transcriptomic work, and also for the opportunity to work at SCELSE, Singapore.

My acknowledgement also goes to the member of Harry Lab (Daniel Bouzo, Dr. Isabella Hadjuk, Dr. Kenardy Kusuma, Dr. Matthew Payne, Dr. Nural Cocketin, and Dr. Shirin Ansari) as well as Gunawan Lab (Kevin Yonathan, Oliver McNeilly, Dr. Riti Mann, and Tina Nguyen) with whom I have the honour of meeting and working with. Thank you for the technical and non-technical discussion, support, and friendship throughout my PhD journey.

I am thankful for technical staffs in Bioscience Laboratory Level 7 (Mercedes Ballesteros and Sarah Osvath) who manage the laboratory and ensure that we all can do our lab work in a proper and safe way. Thank you as well for administration staffs (Meggie Leung, Shannon Hawkins, and Shima Baradaran Vahdat) for their assistance in many administrative works.

I express my gratitude to the office squad (Ahmed Mohammed, Daniela Gaio, Jessica Pedersen, Rami Mazraani, Regan Hayward, Susanna Luo, and William King). Thank you for the scientific and many non-scientific talks that we had, and for the distraction and entertainment that we all definitely need during this PhD candidature. Thank you for the friendship that I will surely cherish all the time.

Acknowledgment also extends to Rosie Hicks, whom I have met through IMNIS program. Thank you for being so humble and grounded, something that I will always remember. Thank you for the relationship that we have built so far and for the advices especially about interpersonal skills.

I am deeply thankful for my families in Christ, Indonesian Christian Macquarie Fellowship (Christopher and Kaitlin Antony, Christopher Townsend, Ellen Paulin Hutagaol, Emman Marpaung, Febrina Sandra, Harry Tjondro and Raniwidia Basileia, Inggrika Remalia Kaban, Jessica Levina Halim, Julie Holmes, Kian and Liza Holik, Lyndle Hardstaff, Merinda Naraswari, Pauline Djojo, Rafael Alvin, Renny Dese, Richard Kusnadi, and Vanie Patiung), Trinity Chapel Macquarie (Dave and Sue Steele-Smith, Ingrid Wei, Tim Mildenhall, Vonnie and Yonnie Ho), Macquarie Chapel Indonesian Church (Ari and Sophia Supala, Gitta Ernestine, Pudi Muliawan and Irene Marius, Steven Lee and Irene Tedjasaputra, and Tirta and Lina Hadinata). Thank you for your love, friendship, support, and especially prayers.

My appreciation also extends to my family back home, especially for Mamski and Papski, who let their youngest and only daughter to move far away from home 8 years ago to pursue her MS and now PhD degree. Thank you for believing in what I would like to pursue, acquire, and choose back then and now.

Although my words will not be sufficient to describe it, I would like to express my profound gratefulness to Roy Simorangkir, my best friend and partner in life. Thank you for being the core of my support system and being a great exemplary of persistence, consistence, and hard work. Thank you for being my solid rock and always have my back during times when I feel like giving up. Thank you for celebrating with me during good times but also praying and crying with me during difficult times. Above all, you have taught and showed me the unconditional love that Jesus himself gave to us and I am truly grateful to have met you in this life, and even more to share this life with you. I love you with all my heart.

Last but not least, Thank you Jesus Christ, for granting me my faith and identity in You alone. I am honoured and privileged to be able to call You Father and to be liberated from the identity other than in You. Praising You for all the people You have surrounded me with and for the wonderful work that You have done.



# Abstract

The widespread use of silver nanoparticle (NAg) in consumer products has prompted major concerns for bacterial resistance phenomena. Scholarly works have reported the natural ability of bacteria to develop resistance to the antibacterial nanoparticle. While the adaptation mechanisms have been studied in Gram-negative bacteria, it remains largely unexplored in Gram-positive bacteria. This work seeks to investigate the phenomena of NAg resistance in *Staphylococcus aureus*, a Gram-positive bacterium, to unravel the development and mechanisms of resistance in one of the WHO-listed priority pathogens.

Herein, the work found that *S. aureus* has the ability to evolve stable resistance traits, reducing the potency of NAg, upon prolonged exposure. Higher NAg concentrations are required to inhibit the bacterium growth when compared to the wild-type strain. A whole genome analysis of the resistant strain revealed mutation in gene that encodes the purine operon repressor protein. The mutation was thought to be responsible, at least in part, for the physiological adaptation of *S. aureus*, that is, the defence responses that manifest even in the absence of the nanoparticle. The role of this mutation was supported by transcriptomic analysis, whereby, increased expression of the whole purine synthesis operon were detected in the resistant strain. This, along with the observed changes in the expression of other metabolic genes (the pyrimidine, nitrogen, and capsular polysaccharide), highlight a metabolic adaptation to the likely disruptions in bacterial fitness.

The transcriptomic analysis also gives insights into the roles of specific cellular pathways, most likely responsible for the resistance characteristics. Our study found increased expression of genes that encode transporter proteins, ROS (reactive oxygen species) scavenger enzymes in the resistant strain and genes that are associated with the assembly of the iron-sulphur (Fe-S) clusters, one of the main cellular targets of NAg. For the latter, the upregulation was detected in the clusters' main synthesis genes (*suf* system) as well as in the iron and cysteine acquisition genes. Collectively, the adaptation mechanisms involve attempt by the bacterium to neutralize the over-production of ROS, while simultaneously recovering the damaged Fe-S clusters and facilitating silver efflux.

In summary, the knowledge generated herein provides insights into the emergence and molecular basis of NAg resistance in a bacterium that has been perceived to have no, or very low resistance tendency to NAg. The fundamental knowledge will allow

development of technologies to overcome the resistance phenomena and to inform strategies for an effective long term use of the nanoparticle.

# List of publications

## Journal article

E. Valentin, A. L. Bottomley, G. S. Chilambi, E. Harry, R. Amal, G. A. Sotiriou, S. A. Rice and C. Gunawan. (2020) Heritable Nanosilver Resistance in Priority Pathogen: A Unique Genetic Adaptation and Comparison with Ionic Silver and Antibiotic. *Nanoscale*, **12**, 2384 – 2392. DOI: 10.1039/C9NR08424J.

## Conference articles

C. Gunawan\*, E. Valentin, A. L. Bottomley, G. A. Sotiriou, S. A. Rice, R. Amal, E. J. Harry. Nanosilver Resistance in Priority Pathogen: Molecular Basis of Adaptation. **International Conference of Energy and Healthcare Materials (ICEHM)**, Sydney, Australia, 30 September-2 October 2020. (invited oral presentation)

C. Gunawan\*, E. Valentin, R. Mann, O. McNeilly, A. L. Bottomley, G. A. Sotiriou, S. A. Rice, R. Amal, E. J. Harry. Genetically-Encoded Nanosilver Resistance in Priority Pathogen. **International Conference on Nanoscience and Nanotech**, Brisbane, Australia, 9-13 February 2020. (oral presentation)

E. Valentin\*, A. L. Bottomley, E. Harry, R. Amal, G. A. Sotiriou, S. A. Rice and C. Gunawan. The emergence of silver nanoparticle resistance to priority Gram-positive pathogenic bacteria. **1<sup>st</sup> International Young Scientist Forum (IYSF) of the 12<sup>th</sup> International Particle Toxicology Conference (IPTC)**, Salzburg, Austria, 9-13 September 2019. (oral presentation)

C. Gunawan\*, E. Valentin, R. Mann, O. McNeilly, A. L. Bottomley, G. A. Sotiriou, S. A. Rice, W. Y. Teoh, C. P. Marquis, R. Amal, E. J. Harry. Nanosilver and Priority Pathogen: Development of Resistance. **10<sup>th</sup> International Nanomedicine Conference**, Sydney, Australia, 24-26 June 2019. (oral presentation)

C. Gunawan\*, E. Valentin, O. McNeilly, A. L. Bottomley, G. A. Sotiriou, S. A. Rice, W. Y. Teoh, C. P. Marquis, R. Amal, E. J. Harry. The Emergence of Bacterial Resistance to Nanoparticles. **6<sup>th</sup> International Conference on Antibiotics, Antimicrobials and Resistance**, Edinburgh, UK, 11-12 October 2018. (invited oral presentation)

\* presenting author



# Table of Contents

---

<b>Acknowledgment</b> .....	<b>i</b>
<b>Abstract</b> .....	<b>v</b>
<b>List of publications</b> .....	<b>vii</b>
<b>List of Tables</b> .....	<b>xiii</b>
<b>List of Figures</b> .....	<b>xv</b>
<b>Abbreviations</b> .....	<b>xix</b>
<b>Chapter 1 Introduction</b> .....	<b>1</b>
<b>Chapter 2 Literature Review</b> .....	<b>3</b>
2.1. Summary .....	3
2.2. Generation of Bioavailable Silver Species from NAg Particles .....	3
2.2.1. Mechanisms of Ag <sup>+</sup> ion release.....	3
2.2.2. Effect of NAg physicochemical characteristics on Ag <sup>+</sup> release and antibacterial activity.....	5
2.2.3. Bioavailable Ag: Interactions of silver with chemical moieties .....	7
2.3. Modes of NAg Antibacterial Activity .....	11
2.3.1. Interactions of NAg with cell envelope .....	11
2.3.2. Cellular internalization of NAg and its internal targets.....	13
2.3.3. Generation of intracellular reactive oxygen species (ROS).....	17
2.4. Bacterial Defence to NAg Antibacterial Activity .....	19
2.4.1. Endogenous and Exogenous Resistance Determinants to Ag <sup>+</sup> ions .....	19
2.4.2. Bacterial resistance to NAg .....	23
2.5. Knowledge Gaps .....	26
<b>Chapter 3 The Emergence of Resistance to NAg and Ag<sup>+</sup> in pathogenic <i>S. aureus</i></b> .....	<b>29</b>
3.1. Summary .....	29
3.2. Introduction.....	29
3.3. Experimental Methods.....	31
3.3.1. Preparation of antibacterial agents.....	31
3.3.2. Determination of Minimum Inhibitory Concentration (MIC).....	32
3.3.3. Visual observation of lysostaphin-suspended <i>S. aureus</i> .....	32
3.3.4. Resistance development of <i>S. aureus</i> in response to NAg, Ag <sup>+</sup> and ciprofloxacin exposure.....	32
3.3.5. Stabilization of resistance genes and new MIC determination for of the resistant strains.....	33

3.4.	Results and Discussion.....	35
3.4.1.	Minimum inhibitory concentration (MIC) of NAg, Ag <sup>+</sup> , and ciprofloxacin on <i>S. aureus</i> WT.....	35
3.4.2.	Adaptation responses of <i>S. aureus</i> to prolonged NAg, Ag <sup>+</sup> and ciprofloxacin exposure .....	36
3.4.3.	Adaptation responses from the 'resistant' <i>S. aureus</i> to NAg, Ag <sup>+</sup> , and ciprofloxacin.....	40
3.4.4.	NAg and Ag <sup>+</sup> cross-resistance.....	43
3.4.5.	Responses to other antibiotics.....	45
3.5.	Conclusions .....	50
<b>Chapter 4</b>	<b>Identification of genetic adaptation in NAg- and Ag<sup>+</sup>-resistant <i>S. aureus</i> strains .....</b>	<b>53</b>
4.1.	Summary.....	53
4.2.	Introduction .....	54
4.3.	Materials and Methods.....	55
4.3.1.	Whole genome comparison study.....	55
4.3.2.	Gene inactivation via CRISPR interference (CRISPRi).....	56
4.3.3.	Determination of minimum inhibitory concentration (MIC) of <i>S. aureus</i> JE2 .....	62
4.4.	Results and Discussion.....	63
4.4.1.	Genetic adaptation of NAg- and Ag <sup>+</sup> -resistant <i>S. aureus</i> strain .....	63
4.4.2.	The role of the mutations to NAg and Ag <sup>+</sup> resistance .....	71
4.5.	Conclusion .....	76
4.6.	Supplementary Information .....	77
<b>Chapter 5</b>	<b>Toxicity Responses of <i>S. aureus</i> to NAg or Ag<sup>+</sup>.....</b>	<b>79</b>
5.1.	Summary.....	79
5.2.	Introduction .....	79
5.3.	Experimental Methods .....	81
5.3.1.	Preparation of antibacterial agents .....	81
5.3.2.	Determination of NAg and Ag <sup>+</sup> concentration for the transcriptomic study.. .....	81
5.3.3.	Sample preparation for RNA extraction.....	81
5.3.4.	RNA extraction .....	82
5.3.5.	RNA quality control.....	82
5.3.6.	RNA sequencing (RNA-seq) and read mapping .....	82
5.3.7.	RNA-seq data analysis.....	83
5.4.	Results and Discussion.....	83

5.4.1.	Determination of NAg and Ag <sup>+</sup> concentration to treat the WT strain .....	83
5.4.2.	Variation analysis between samples .....	85
5.4.3.	Comparison of differentially expressed genes in the WT strain treated with NAg and Ag <sup>+</sup> .....	86
5.4.4.	Toxicity responses to NAg .....	88
5.5.	Conclusion.....	96
5.6.	Supplementary Information.....	98
<b>Chapter 6</b>	<b>Defence Mechanisms of Resistant <i>S. aureus</i> to NAg or Ag<sup>+</sup> .....</b>	<b>103</b>
6.1.	Summary .....	103
6.2.	Introduction.....	104
6.3.	Experimental Methods.....	105
6.3.1.	Preparation of antibacterial agents.....	105
6.3.2.	Bacterial strains .....	105
6.3.3.	Growth responses following NAg or Ag <sup>+</sup> exposure .....	105
6.3.4.	Sample preparation for RNA extraction .....	106
6.3.5.	RNA extraction, RNA quality control, RNA sequencing and read mapping, and RNA-seq data analysis .....	106
6.4.	Results and Discussion .....	106
6.4.1.	Growth responses following NAg and Ag <sup>+</sup> exposure .....	106
6.4.2.	Variation analysis between samples .....	109
6.4.3.	Comparison of differentially expressed genes in the NAg- and Ag <sup>+</sup> -resistant strains.....	110
6.4.4.	Physiological adaptations of the NAg- and Ag <sup>+</sup> -resistant strain.....	113
6.4.5.	Resistance responses of the NAg- and Ag <sup>+</sup> -resistant strain in the presence of silver .....	127
6.5.	Conclusion.....	145
6.6.	Supplementary Information.....	146
<b>Chapter 7</b>	<b>General Discussion and Future Directions .....</b>	<b>221</b>
7.1.	General discussion.....	221
7.1.1.	The emergence of NAg resistance is likely widespread across different species. ....	222
7.1.2.	Potential defence mechanisms in NAg and Ag <sup>+</sup> -resistant <i>S. aureus</i> ....	223
7.1.3.	The defence mechanisms to NAg is unlikely a species-specific mechanism.....	225
7.1.4.	NAg source of toxicity potentially originates from soluble silver and solid particulate.....	226
7.2.	Future directions.....	227

7.2.1.	The potential spread and development of NAg resistance. ....	227
7.2.2.	Identification of novel targets to fight off resistance .....	228
<b>References</b>	.....	<b>233</b>

# List of Tables

<b>Table 4.1.</b> List of primers used to validate the identified mutations in the NAg- and Ag <sup>+</sup> -resistant strains.....	56
<b>Table 4.2.</b> List of primers used to construct sgRNA plasmid. Base-pairing sequences for each gene target were highlighted in bold.....	58
<b>Table 4.3.</b> The list of antibiotic used for plasmid selection.....	59
<b>Table 4.4.</b> List of <i>S. aureus</i> JE2 (USA300 JE2) strains used in this study .....	62
<b>Table 4.5.</b> Number of non-synonymous mutations identified in NAg- and Ag <sup>+</sup> -resistant strain. The mutations were confirmed to present in multiple isolates upon validation <i>via</i> Sanger sequencing.....	64
<b>Table 4.6.</b> Mutations in NAg-resistant <i>S. aureus</i> genome.....	69
<b>Table 4.7.</b> Mutations in Ag <sup>+</sup> -resistant <i>S. aureus</i> genome .....	69
<b>Table 5.1.</b> Treatment conditions used for transcriptomic study in the WT strain.....	82
<b>Table 5.2.</b> Number of upregulated and downregulated genes in the WT strain treated with NAg and Ag <sup>+</sup> compared to the no-treatment.....	86
<b>Table 6.1</b> Treatment conditions used in transcriptomic study for the wild-type (WT), NAg-resistant (NAg-r) and Ag <sup>+</sup> -resistant (Ag-r) strains .....	106
<b>Table 6.2.</b> Total genes differentially expressed in different NAg treatments in the NAg-resistant strain.....	111
<b>Table 6.3.</b> Total genes differentially expressed in different Ag <sup>+</sup> treatments in the Ag <sup>+</sup> -resistant strain.....	111



# List of Figures

<b>Figure 2.1.</b> Representative scheme of Ag <sup>+</sup> ions release from NAg and their interaction to surroundings <sup>47</sup> .....	10
<b>Figure 2.2.</b> Schematic diagram of Gram-positive and Gram-negative cell surface <sup>49</sup> . CAP: covalently attached protein; WTA: wall teichoic acid; LTA: lipoteichoic acid; LPS: lipopolysaccharide; OMP: outer membrane protein; IMP: integral membrane protein. ....	11
<b>Figure 2.3.</b> Proposed mechanism of A) NAg interaction and B) cell wall pit formation in bacterial cell wall <sup>51</sup> .....	12
<b>Figure 2.4.</b> The internal structure of <i>S. aureus</i> observed by TEM A) without and B) with NAg exposure <sup>7</sup> .....	16
<b>Figure 2.5.</b> Schematic representative of OmpF and OmpC porins in the presence of Ag <sup>+</sup> .....	19
<b>Figure 2.6.</b> Schematic representative of Cus system in the presence of Ag <sup>+</sup> .....	20
<b>Figure 2.7.</b> Schematic representative of Sil system in the presence of Ag <sup>+</sup> .....	22
<b>Figure 2.8.</b> Growth of the resistant <i>B. subtilis</i> NAg (0 – 10 mg/L) following the pre-exposure (3 or 7 mg/L NAg) when compared to the control <sup>94</sup> .....	25
<b>Figure 2.9.</b> Aggregation of NAg (red arrow) by <i>E. coli</i> following 24 h inoculation, shown with TEM <sup>11</sup> .....	26
<b>Figure 3.1.</b> Schematic diagram of <i>S. aureus</i> resistance development methodology in increasing concentration of antibacterial agents.....	34
<b>Figure 3.2.</b> Sampling methods prior to the new MIC determination following the prolonged antimicrobial exposures (passaging) of <i>S. aureus</i> .....	34
<b>Figure 3.3.</b> Dose-dependent growth response of <i>S. aureus</i> WT growth relative to cell-only control in (A) NAg (1 to 5 µg Ag/mL), (B) Ag <sup>+</sup> (1 to 5 µg Ag/mL), and (C) Ciprofloxacin (0.25 to 4 µg Ag/mL) to determine their respective minimum inhibitory concentration (MIC). ....	35
<b>Figure 3.4.</b> Prolonged exposure of <i>S. aureus</i> WT to NAg (circle), Ag <sup>+</sup> (diamond), and ciprofloxacin (triangle) <i>via</i> sub-culturing. <i>S. aureus</i> WT was exposed for 50 days to NAg and Ag <sup>+</sup> (A and C) or 30 days to ciprofloxacin (B and D) with progressive increases in antibacterial concentration.. ....	38
<b>Figure 3.5.</b> Growth responses of ciprofloxacin-passaged (triangle) and WT (square) strain to increasing concentration of ciprofloxacin.....	41
<b>Figure 3.6.</b> Growth responses of NAg-passaged (circle) and WT (square) strain to increasing concentration of NAg.....	42
<b>Figure 3.7.</b> Growth responses of Ag <sup>+</sup> -passaged (diamond) and the WT (square) strain to increasing concentration of Ag <sup>+</sup> .....	43
<b>Figure 3.8.</b> Growth responses of NAg-resistant strain (circle) in increasing concentration of Ag <sup>+</sup> (A) and Ag <sup>+</sup> -resistant strain (diamond) in increasing concentrations of NAg (B) as compared to the WT strain (square).. ....	44
<b>Figure 3.9.</b> Growth responses of ciprofloxacin-resistant (triangle) and WT (square) strain to increasing concentration of NAg (A) and Ag <sup>+</sup> (B).. ....	45
<b>Figure 3.10.</b> Growth responses of NAg-resistant strain (circle), Ag <sup>+</sup> -resistant strain (diamond) and <i>S. aureus</i> WT strain (square) to increasing concentration of A) ciprofloxacin, B) vancomycin, C) methicillin, and D) cefotaxime.. ....	47

<b>Figure 3.11.</b> The resistance mechanism of $\beta$ -lactams antibiotics and vancomycin in <i>S. aureus</i> .....	48
<b>Figure 3.12.</b> Effect of antistaphylococcal agent to silver-resistant <i>S. aureus</i> .....	50
<b>Figure 4.1.</b> Process flow diagram for gene inactivation <i>via</i> CRISPRi.....	57
<b>Figure 4.2.</b> Map of A) sgRNA plasmid and B) dCas9 plasmid for CRISPRi.....	60
<b>Figure 4.3.</b> Schematic diagram of sgRNA plasmid construction. The sequences in the plasmid are colour-coded and explained in the bottom left corner. Primer-R: reverse primer, Primer-F: forward primer.....	61
<b>Figure 4.4.</b> The observed mutations and hypothesized effect in the genes encode for putative purine operon repressor PurR in NAg-resistant strains (A), L-cystine binding protein TcyA and cysteine metabolism regulator CymR (B) identified in NAg and Ag <sup>+</sup> -resistant strains isolates .....	66
<b>Figure 4.5.</b> Schematic diagram of CRISPR and CRISPRi. RNAP: RNA polymerase. Adapted from <sup>150</sup> .....	72
<b>Figure 4.6.</b> Growth responses of <i>S. aureus</i> JE2 (square) and JE2 mutants in increasing concentration of NAg- (A) or Ag <sup>+</sup> (B) when compared to the cell-only control. ....	75
<b>Figure 5.1.</b> Growth curve of the WT strain treated with (A) NAg and (B) Ag <sup>+</sup> at different concentrations compared to the untreated (circle) as measured by the optical density at 600 nm.....	84
<b>Figure 5.2.</b> Principal component analysis (PCA) of different treatment groups (no treatment, NAg treatment and Ag <sup>+</sup> treatment) to <i>S. aureus</i> WT strain and its biological replicates.....	85
<b>Figure 5.3.</b> The number of differentially expressed genes on the <i>S. aureus</i> WT strain treated with NAg and Ag <sup>+</sup> compared to the untreated WT strain.....	87
<b>Figure 5.4.</b> The distribution of differentially expressed genes (A) and the number of upregulated (green) and downregulated (red) genes (B) classified based on the functional pathway in NAg-WT when compared to the no-treatment.....	89
<b>Figure 5.5.</b> A proposed model for <i>S. aureus</i> toxicity response to NAg <i>via</i> iron uptake and D-alanylation of teichoic acid. ....	92
<b>Figure 6.1.</b> Growth curve of the wild-type (WT) and NAg-resistant (NAg-r) strains in the absence (square and circle, respectively) and presence of different NAg concentrations as measured by the optical density at 600 nm.....	107
<b>Figure 6.2.</b> Growth curve of the wild-type (WT) and Ag <sup>+</sup> -resistant (Ag-r) strains in the absence (square and circle, respectively) and presence of different Ag <sup>+</sup> concentrations as measured by the optical density at 600 nm.....	108
<b>Figure 6.3.</b> Principal component analysis (PCA) plot of the gene expression profile of 9 treatment groups and its biological replicates.....	109
<b>Figure 6.4.</b> Venn diagram representing the number of genes expressed from untreated (NT) NAg-resistant (NAg-r) strain and Ag <sup>+</sup> -resistant (Ag-r) strain when compared to the untreated wild-type (WT) strain. ....	113
<b>Figure 6.5.</b> Heat map representing the level of expression in some of the common differentially expressed genes in the untreated (NT) NAg-resistant (NAg-r) strain and the Ag <sup>+</sup> -resistant (Ag-r) strain. ....	114
<b>Figure 6.6.</b> The proportion (A), number of upregulated and downregulated (B) differentially expressed genes (DEGs) based on the functional pathway, and dot plot (C) representing the distribution of DEGs based on their log <sub>2</sub> fold change in the untreated NAg-resistant strain with respect to the WT strain of <i>S. aureus</i> .....	118

<b>Figure 6.7.</b> <i>De novo</i> purine nucleotide synthesis pathway in <i>S. aureus</i> .....	120
<b>Figure 6.8.</b> <i>De novo</i> pyrimidine nucleotide synthesis pathway in <i>S. aureus</i> .....	121
<b>Figure 6.9.</b> Nitrate reduction to ammonia pathway in <i>S. aureus</i> .....	122
<b>Figure 6.10.</b> Capsular polysaccharide synthesis from UDP-D-GlcNAc and lipid I synthesis (inside a box) pathway in <i>S. aureus</i> .....	124
<b>Figure 6.11.</b> Venn diagram representing the number of significantly expressed genes in the NAg-r high-NAg and Ag-r high-Ag samples.....	128
<b>Figure 6.12.</b> Venn diagram representing the number of significantly expressed genes from different strains and NAg exposure.....	129
<b>Figure 6.13.</b> Heat map representing the level of expression of the common DEGs observed when comparing the gene expression in the wild-type strain (WT) when exposed to low NAg concentration (low-NAg), the NAg-resistant (NAg-r) strain when exposed to low-NAg and NAg-r strain when exposed high NAg concentration (high-NAg).....	130
<b>Figure 6.14.</b> The percentage proportion of functional pathways affected (A), the number of upregulated and downregulated DEGs (B), and the distribution of log <sub>2</sub> fold change (C) in the NAg-resistant strain exposed to low NAg concentration (1.5 µg Ag/mL) when compared to the untreated NAg-resistant strain.....	133
<b>Figure 6.15.</b> The percentage proportion of functional pathways affected (A), the number of upregulated and downregulated DEGs (B), and the distribution of log <sub>2</sub> fold change (C) in the NAg-resistant strain exposed to high NAg concentration (4.5 µg Ag/mL) when compared to the untreated NAg-resistant strain.....	134
<b>Figure 6.16.</b> Heat map representing the level of expression of ATP synthesis and pyrimidine synthesis genes observed in the NAg-resistant (NAg-r) strain when exposed to low NAg concentration (low-NAg) and NAg-r strain when exposed to high NAg concentration (high-NAg).....	136
<b>Figure 6.17.</b> Heat map representing the level of expression of ROS scavenger and iron-sulphur (Fe-S) assembly genes observed in the NAg-resistant (NAg-r) strain when exposed to low NAg concentration (low-NAg) and high NAg concentration (high-NAg). .....	138
<b>Figure 6.18.</b> A proposed model of NAg-resistant <i>S. aureus</i> responses to NAg toxicity based on the findings herein. ....	144



# Abbreviations

$\mu$	Micro ( $10^{-6}$ )
Ag <sup>+</sup>	Ionic silver
Ag-r	Ag <sup>+</sup> -resistant strain
ANSTO	Australia's Nuclear Science and Technology Organisation
ASV	Anodic stripping voltammetry
ATP	Adenosine monophosphate
ATR	Attenuated total reflection
<i>B.</i>	Bacillus
BET	Brunauer–Emmett–Teller
BOD	Biological oxygen demand
BPEI	Branched polyethyleneimine
Ca-MHB	Cation-adjusted Mueller Hinton broth
CLSI	The Clinical and Laboratory Standards Institute
CRISPRi	Clustered regularly interspaced short palindromic repeats interference
CSR	the Centre for Staphylococcal Research
d	Diameter
dCas9	dead Cas9
DEGs	Differentially expressed genes
DNA	Deoxyribonucleic acid
dTEM	Diameter based on transmission electron microscopy
<i>E.</i>	Escherichia
EDAX	Energy dispersive X-ray spectroscopy
EXAFS	Extended X-ray fine absorption structure
Fe-S cluster	Iron-sulphur cluster
FSP	Flame spray pyrolysis

FT-IR	Fourier transform infrared
GSH	Glutathione
GSSG	Oxidized glutathione
h	Hour
HGT	Horizontal gene transfer
ICP-MS	Inductively coupled plasma spectrometry-mass spectrometry
IMP	Integral membrane protein
IMP	Inosine monophosphate
LB	Luria Bertani broth
LPS	Lipopolysaccharide
LTA	Lipoteichoic acid
MALDI-TOF	Matrix-assisted laser desorption/ionization-time of flight
MBC	Minimum bactericidal concentration
MHA	Cation-adjusted Mueller Hinton agar
MIC	Minimum inhibitory concentration
min	Minute
MRSA	Methicillin-resistant <i>S. aureus</i>
NAg	Silver nanoparticle
NAG	N-acetylglucosamine
NAg-r	NAg-resistant strain
NAM	N-acetylmuramic acid
NCBI	National Centre of Biotechnology Information
OD	Optical density
Omp	Outer membrane protein
ORF	Open reading frame
<i>P.</i>	<i>Pseudomonas</i>
PAM	Protospacer adjacent motive
PBP	Penicillin binding proteins

PCA	Principal component analysis
PCR	Polymerase chain reaction
PEG	Polyethylene glycol
PGRE	Pomegranate rind extract
PVP	Polyvinylpyrrolidone
qPCR	Quantitative polymerase chain reaction
RNA	Ribonucleic acid
RNA-seq	RNA-sequencing
ROS	Reactive oxygen species
RPM	Rotation per minute
S.	Staphylococcus
SCELSE	Singapore Centre for Environmental Life Science Engineering
SDS-PAGE	Sodium dodecyl sulphate-polyacrylamide gel electrophoresis
SEM	Scanning electron microscopy
SERS	Surface-enhanced Raman spectroscopy
sgRNA	single guide RNA
SNV	Single nucleotide variants
TCA cycle	Citric acid cycle
TEM	Transmission electron microscopy
TRFLP	Terminal restriction fragment length polymorphism
UMP	Uridine monophosphate
UV	Ultra violet
WHO	World Health Organization
WT	Wild-type strain
wt%	Weight percentage
WTA	Wall teichoic acid
XRD	X-ray diffraction

